Published in Ann Cardiothorac Surg on November 01, 2012
Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study. Lancet Oncol (2011) 4.66
Ecological association between asbestos-related diseases and historical asbestos consumption: an international analysis. Lancet (2007) 3.80
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: multi-institutional experience. J Clin Oncol (2009) 3.04
Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients. J Thorac Cardiovasc Surg (2008) 2.93
Prevention, early detection, and management of complications after 328 consecutive extrapleural pneumonectomies. J Thorac Cardiovasc Surg (2004) 2.53
High blood neutrophil-to-lymphocyte ratio is an indicator of poor prognosis in malignant mesothelioma patients undergoing systemic therapy. Clin Cancer Res (2010) 2.50
Pleuropneumonectomy in the management of diffuse malignant mesothelioma of the pleura. Experience with 29 patients. Thorax (1976) 2.38
Increasing incidence of malignant mesothelioma after exposure to asbestos during home maintenance and renovation. Med J Aust (2011) 2.30
Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma. J Clin Oncol (2009) 2.26
Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. Chest (1998) 2.18
Global mesothelioma deaths reported to the World Health Organization between 1994 and 2008. Bull World Health Organ (2011) 2.16
Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience. J Clin Oncol (1998) 2.15
Neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. J Clin Oncol (2004) 1.92
Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. Ann Oncol (2007) 1.85
Trimodality therapy for malignant pleural mesothelioma: results from an EORTC phase II multicentre trial. Eur Respir J (2010) 1.74
Inflammation-based prognostic indices in malignant pleural mesothelioma. J Thorac Oncol (2012) 1.70
Asbestos-induced lung diseases: an update. Transl Res (2009) 1.66
A novel prognostic model for malignant mesothelioma incorporating quantitative FDG-PET imaging with clinical parameters. Clin Cancer Res (2010) 1.48
Trimodality therapy with induction chemotherapy followed by extrapleural pneumonectomy and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J Clin Oncol (2009) 1.48
Surgical assessment of malignant pleural mesothelioma: have we reached a critical stage? Eur J Cardiothorac Surg (2010) 1.45
Induction chemotherapy, extrapleural pneumonectomy (EPP) and adjuvant hemi-thoracic radiation in malignant pleural mesothelioma (MPM): Feasibility and results. Lung Cancer (2007) 1.40
Pleural mesothelioma: little evidence, still time to do trials. Lancet (2004) 1.38
Low calretinin expression and high neutrophil-to-lymphocyte ratio are poor prognostic factors in patients with malignant mesothelioma undergoing extrapleural pneumonectomy. J Thorac Oncol (2011) 1.35
The importance of surgical staging in the treatment of malignant pleural mesothelioma. J Thorac Cardiovasc Surg (1996) 1.30
Incidence and management of complications after neoadjuvant chemotherapy followed by extrapleural pneumonectomy for malignant pleural mesothelioma. Eur J Cardiothorac Surg (2006) 1.28
Induction chemotherapy, extrapleural pneumonectomy, and postoperative high-dose radiotherapy for locally advanced malignant pleural mesothelioma: a phase II trial. J Thorac Oncol (2006) 1.28
Exploratory analysis of activation of PTEN-PI3K pathway and downstream proteins in malignant pleural mesothelioma (MPM). Lung Cancer (2012) 1.22
Validation of prognostic factors in malignant pleural mesothelioma: a retrospective analysis of data from patients seeking compensation from the New South Wales Dust Diseases Board. Clin Lung Cancer (2012) 1.22
Cytoreductive surgery combined with intraoperative hyperthermic intrathoracic chemotherapy for stage I malignant pleural mesothelioma. Ann Surg Oncol (2003) 1.19
Malignant pleural mesothelioma: a population-based study of survival. J Thorac Oncol (2010) 1.17
The relationship between volume or surgeon specialty and outcome in the surgical treatment of lung cancer: a systematic review and meta-analysis. J Thorac Oncol (2012) 1.15
Surgical options in malignant pleural mesothelioma: extrapleural pneumonectomy or pleurectomy/decortication. Semin Thorac Cardiovasc Surg (2009) 1.13
The MARS feasibility trial: conclusions not supported by data. Lancet Oncol (2011) 1.13
Node status has prognostic significance in the multimodality therapy of diffuse, malignant mesothelioma. J Clin Oncol (1993) 1.08
A proposed new international TNM staging system for malignant pleural mesothelioma from the International Mesothelioma Interest Group. Lung Cancer (1996) 1.07
Circulating and tumor-infiltrating myeloid cells predict survival in human pleural mesothelioma. Cancer (2011) 1.06
Extrapleural pneumonectomy for early stage malignant pleural mesothelioma: a harmful procedure. Lung Cancer (2012) 1.04
A phase II trial of pleurectomy/decortication followed by intrapleural and systemic chemotherapy for malignant pleural mesothelioma. J Clin Oncol (1994) 1.02
Soluble mesothelin, megakaryocyte potentiating factor, and osteopontin as markers of patient response and outcome in mesothelioma. J Thorac Oncol (2011) 1.00
The ticking time-bomb of asbestos: its insidious role in the development of malignant mesothelioma. Crit Rev Oncol Hematol (2012) 0.93
Improving survival results after surgical management of malignant pleural mesothelioma: an Australian institution experience. Ann Thorac Cardiovasc Surg (2011) 0.91
Contemporary management of malignant pleural mesothelioma. Oncologist (1999) 0.91
The evolution of multimodality therapy for malignant pleural mesothelioma. Curr Treat Options Oncol (2011) 0.88
Aquaporin 1 is an independent prognostic factor in pleural malignant mesothelioma. Cancer (2011) 0.87
A resectable form of multiple mesothelioma. Dis Chest (1959) 0.84
Bilateral thoracoscopy, mediastinoscopy and laparoscopy, in addition to CT, MRI and PET imaging, are essential to correctly stage and treat patients with mesothelioma prior to trimodality therapy. ANZ J Surg (2009) 0.83
The proposed new international TNM staging system for malignant pleural mesothelioma: application to imaging. AJR Am J Roentgenol (1996) 0.82
Surgical treatment in the management of malignant pleural mesothelioma: a single institution's experience. Ann Surg Oncol (2008) 0.82
Surgical management of malignant pleural mesothelioma: a systematic review and evidence summary. Lung Cancer (2005) 0.82
Extrapleural pneumonectomy or supportive care: treatment of malignant pleural mesothelioma? Interact Cardiovasc Thorac Surg (2011) 0.79
Pharmacokinetics of doxorubicin and cisplatin used in intraoperative hyperthermic intrathoracic chemotherapy after cytoreductive surgery for malignant pleural mesothelioma and pleural thymoma. Anticancer Drugs (2003) 0.79
The value of chest computer tomography and cervical mediastinoscopy in the preoperative assessment of patients with malignant pleural mesothelioma. Ann Thorac Surg (2003) 0.79
Asbestos-related malignancy. Crit Rev Oncol Hematol (1986) 0.77
Primum non nocere? Does this also apply to mesothelioma? Lung Cancer (2012) 0.76
Prospective Registry On Mesothelioma Peritonei Treatment (PROMPT): study design and rationale. Tumori (2012) 0.76
Haemolysis during sample preparation alters microRNA content of plasma. PLoS One (2011) 2.92
Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C. Mol Cancer Ther (2002) 2.60
Characterization of the MRP4- and MRP5-mediated transport of cyclic nucleotides from intact cells. J Biol Chem (2003) 1.63
Steroid and bile acid conjugates are substrates of human multidrug-resistance protein (MRP) 4 (ATP-binding cassette C4). Biochem J (2003) 1.57
The Impact of Hemolysis on Cell-Free microRNA Biomarkers. Front Genet (2013) 1.54
Interactions between hepatic Mrp4 and Sult2a as revealed by the constitutive androstane receptor and Mrp4 knockout mice. J Biol Chem (2004) 1.46
Low calretinin expression and high neutrophil-to-lymphocyte ratio are poor prognostic factors in patients with malignant mesothelioma undergoing extrapleural pneumonectomy. J Thorac Oncol (2011) 1.35
Does miR-1 play a role in malignant pleural mesothelioma development and progression? Chest (2013) 1.09
The ABC transporter BCRP/ABCG2 is a placental survival factor, and its expression is reduced in idiopathic human fetal growth restriction. FASEB J (2007) 1.07
Evidence for two interacting ligand binding sites in human multidrug resistance protein 2 (ATP binding cassette C2). J Biol Chem (2003) 1.07
Protein kinase C activation downregulates human organic anion transporter 1-mediated transport through carrier internalization. J Am Soc Nephrol (2003) 1.06
YB-1, the E2F pathway, and regulation of tumor cell growth. J Natl Cancer Inst (2011) 1.04
A rapid and sensitive method to detect siRNA-mediated mRNA cleavage in vivo using 5' RACE and a molecular beacon probe. Nucleic Acids Res (2009) 1.02
Therapeutic and biological importance of getting nucleotides out of cells: a case for the ABC transporters, MRP4 and 5. Adv Drug Deliv Rev (2002) 1.01
Cell-free microRNAs: potential biomarkers in need of standardized reporting. Front Genet (2013) 0.97
Increased circulating miR-625-3p: a potential biomarker for patients with malignant pleural mesothelioma. J Thorac Oncol (2012) 0.94
Challenges and controversies in the diagnosis of malignant mesothelioma: Part 2. Malignant mesothelioma subtypes, pleural synovial sarcoma, molecular and prognostic aspects of mesothelioma, BAP1, aquaporin-1 and microRNA. J Clin Pathol (2013) 0.91
Modulatory effects of curcumin on multi-drug resistance-associated protein 5 in pancreatic cancer cells. Cancer Chemother Pharmacol (2010) 0.89
The human multidrug resistance protein MRP5 transports folates and can mediate cellular resistance against antifolates. Cancer Res (2005) 0.89
The candidate tumor suppressor gene Ecrg4 as a wound terminating factor in cutaneous injury. Arch Dermatol Res (2012) 0.87
Validation of tissue microarray technology in malignant pleural mesothelioma. Pathology (2011) 0.86
Challenges and controversies in the diagnosis of mesothelioma: Part 1. Cytology-only diagnosis, biopsies, immunohistochemistry, discrimination between mesothelioma and reactive mesothelial hyperplasia, and biomarkers. J Clin Pathol (2013) 0.85
The potency of siRNA-mediated growth inhibition following silencing of essential genes is dependent on siRNA design and varies with target sequence. Oligonucleotides (2009) 0.83
Inflammation in malignant mesothelioma - friend or foe? Ann Cardiothorac Surg (2012) 0.82
Molecular biomarkers in malignant mesothelioma: state of the art. Pathology (2011) 0.80
ZIC1 is silenced and has tumor suppressor function in malignant pleural mesothelioma. J Thorac Oncol (2013) 0.80
Mutational analysis of hedgehog signaling pathway genes in human malignant mesothelioma. PLoS One (2013) 0.79
The importance of RT-qPCR primer design for the detection of siRNA-mediated mRNA silencing. BMC Res Notes (2011) 0.78
Immunohistochemistry in the diagnosis of malignant pleural mesothelioma: trends in Australia and a literature review. Asia Pac J Clin Oncol (2012) 0.78
Long non coding RNAs (lncRNAs) are dysregulated in Malignant Pleural Mesothelioma (MPM). PLoS One (2013) 0.78
Interactions of dietary phytochemicals with ABC transporters: possible implications for drug disposition and multidrug resistance in cancer. Drug Metab Rev (2010) 0.78
Protecting Texas children: evidence-based recommendations for improving childhood vaccination rates. Tex Med (2003) 0.75
Welcome message from conference co-convenors. Asia Pac J Clin Oncol (2014) 0.75